Gland Pharma Ltd - Stock Valuation and Financial Performance

BSE: 543245 | NSE: GLAND | Pharmaceuticals & Drugs | Mid Cap

Gland Pharma Share Price

1,751.95 -41.25 -2.30%
as on 12-Apr'24 10:20

DeciZen - make an informed investing decision on Gland Pharma

Overall Rating
Bole Toh

1. Quality

2. Valuation


3. Price Trend

Gland Pharma stock performance -

mw4me loader
P/E Ratio (SA):
Market Cap:
28,779.1 Cr.
52-wk low:
52-wk high:

Is Gland Pharma Ltd an attractive stock to invest in?

1. Is Gland Pharma Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Gland Pharma Ltd is a good quality company.

2. Is Gland Pharma Ltd undervalued or overvalued?

The key valuation ratios of Gland Pharma Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Gland Pharma Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Gland Pharma Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Gland Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Gland Pharma Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 26.1%16.7%18.7%21%13.7%16.6%22%20.3%17.8%10.3%-
Value Creation

Growth Parameters

Growth Parameters Colour Code Guide

Sales 9919941,3481,4791,6202,0442,6333,4634,4013,6173,778
Sales YoY Gr.-0.3%35.6%9.7%9.5%26.2%28.8%31.5%27.1%-17.8%-
Adj EPS 18.61319.42619.828.24659.270.747.248.6
YoY Gr.--30.2%49.7%33.8%-24%42.7%63%28.8%19.4%-33.3%-
BVPS (₹) 70.989108.2134.9155.6184.7234.3359.3434.9482.8526.7
Adj Net
Cash Flow from Ops. 130148224476202185701605791368-
Debt/CF from Ops.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 15.5%17.4%11.2%-17.8%
Adj EPS 10.9%19%0.9%-33.3%
Share Price - - -11.6% 40.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on
Equity %
Op. Profit
Mgn %
Net Profit
Mgn %
Debt to
Working Cap
Cash Conv.

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 11.16%

Return on Equity has declined versus last 3 years average to 9.60%

Net Profit has been subdued in last 3 years 0.88%

Sales growth is not so good in last 4 quarters at -2.66%

Latest Financials - Gland Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 48.6 40
TTM Sales (₹ Cr.) 3,778 4,912
BVPS (₹.) 526.7 516
Reserves (₹ Cr.) 8,659 8,482
P/BV 3.32 3.39
PE 35.92 43.69
From the Market
52 Week Low / High (₹) 861.50 / 2195.75
All Time Low / High (₹) 861.50 / 4350.00
Market Cap (₹ Cr.) 28,779
Equity (₹ Cr.) 16.5
Face Value (₹) 1
Industry PE 48

Management X-Ray of Gland Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Gland Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
Operating Expenses 6306788468541,0851,3381,6782,1612,8902,598
Manufacturing Costs93105120266330412470511275319
Material Costs4124145403754806268361,2192,1091,685
Employee Cost 81106131153179223278311339400
Other Costs 44535459967794119167194
Operating Profit 3613165026255357069551,3021,5111,019
Operating Profit Margin (%) 36.4%31.8%37.3%42.3%33.0%34.6%36.3%37.6%34.3%28.2%
Other Income 93037344986139135224240
Interest 1317166447357
Depreciation 2857637478829599110147
Exceptional Items 00000-20000-56
Profit Before Tax 3272724595785026869931,3351,6191,048
Tax 10363146164180234220338407273
Profit After Tax 2242093144143214527739971,212776
PAT Margin (%) 22.6%21.1%23.3%28.0%19.8%22.1%29.4%28.8%27.5%21.5%
Adjusted EPS (₹)19.013.420.226.720.729.249.961.073.847.1
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)

Equity and Liabilities

Shareholders Fund 8341,3941,6772,0902,4102,8623,6305,8787,1457,952
Share Capital 12161515151515161616
Reserves 8221,3791,6622,0742,3952,8473,6145,8627,1297,935
Minority Interest0000000000
Long Term Debt9277576554443
Short Term Debt5859400000000
Trade Payables986689189292446249396463589
Others Liabilities 204163224189220209203218223229
Total Liabilities 1,2871,7582,0862,4742,9283,5234,0866,4967,8348,773

Fixed Assets

Gross Block5658201,0201,0061,0541,2201,3481,4312,0812,295
Accumulated Depreciation106172232134212291380476579724
Net Fixed Assets4606497888728439299689541,5021,571
CWIP 208192202161199123188338191177
Investments 000000011638
Trade Receivables1681693514184755066026711,075863
Cash Equivalents 773162735336717531,3253,0053,0863,767
Others Assets67111105111228299246252632442
Total Assets 1,2871,7582,0862,4742,9283,5234,0866,4967,8348,773

Cash Flow

(All Figures are in Crores.)
Cash Flow From Operating Activity 130148224476202185701605791368
PBT 3272724595785026869931,3351,6191,048
Adjustment 4357697151763217-2837
Changes in Working Capital -148-117-187-11-193-354-80-436-393-407
Tax Paid -92-64-117-161-157-223-244-311-407-311
Cash Flow From Investing Activity -190-400-12-97-359-314-766-1,525-1,0101,208
Capex -191-263-188-116-85-135-171-228-522-223
Net Investments 0-1571580-298-219-639-1,358-6121,271
Others 120181924404361123161
Cash Flow From Financing Activity 46333-93-116-4-3-71,2383515
Net Proceeds from Shares 073700399001,2253921
Net Proceeds from Borrowing 0-11-31-7100-1-100
Interest Paid -6-14-13-6-3-3-6-2-3-6
Dividend Paid 0000000000
Others 52-379-49-40-399001700
Net Cash Flow -1482119263-160-132-72319-1841,591
ROE (%)31.0218.7920.4221.9714.2717.1423.8120.9718.6210.28
ROCE (%)39.0522.528.3530.0422.4126.1130.682824.8613.97
Asset Turnover Ratio0.910.660.710.650.60.630.690.650.610.44
PAT to CFO Conversion(x)0.580.710.711.150.630.410.910.610.650.47
Working Capital Days
Receivable Days546270941008877677298
Inventory Days871149391100127116107102158
Payable Days6572521351832151529774114

Gland Pharma Ltd Stock News

Gland Pharma Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Gland Pharma on 12-Apr-2024 10:20 is ₹1,752.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Apr-2024 10:20 the market cap of Gland Pharma stood at ₹28,779.1.
The latest P/E ratio of Gland Pharma as of 12-Apr-2024 10:20 is 35.92.
The latest P/B ratio of Gland Pharma as of 12-Apr-2024 10:20 is 3.32.
The 52-week high of Gland Pharma is ₹2,195.8 and the 52-week low is ₹861.5.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gland Pharma is ₹3,778 ( Cr.) .

About Gland Pharma Ltd

The company was incorporated as Gland Pharma Private Limited, a private limited company, at Hyderabad under the Companies Act, 1956 on March 20, 1978 and was granted the certificate of incorporation by the Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of the company was changed to Gland Pharma Limited pursuant to a special resolution passed by the shareholders of the Company on December 5, 1994, and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act, 1956.

The company is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019. It sells its products primarily under a business to business (B2B) model in many countries including the United States, Europe, Canada, Australia, India and the Rest of the world. It has a consistent compliance track record with a range of regulatory regimes across these markets. It also has an extensive track record in complex injectables development, manufacturing and marketing and a close understanding of the related sophisticated scientific, technical and regulatory processes. It was established in Hyderabad, India in 1978 and has expanded from liquid parenterals to cover other elements of the injectables value chain, including contract development, own development, dossier preparation and filing, technology transfer and manufacturing across a range of delivery systems. It has a professional management team and one of its Promoters, Shanghai Fosun Pharma, is a global pharmaceutical major.

Business area of company

The company is focused on meeting diverse injectables needs with a stable supply of affordable and high quality products. It has established a portfolio of injectable products across various therapeutic areas and delivery systems. It is present in sterile injectables, oncology and ophthalmics, and focus on complex injectables, NCE-1s, First-to-File products and 505(b)(2) filings. Its delivery systems include liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops. It is expanding its development and manufacturing capabilities in complex injectables such as peptides, long-acting injectables, suspensions and hormonal products as well as new delivery systems such as pens and cartridges.

Awards, accreditations and recognitions:


  • Awarded the ‘Outstanding Exports Performance Award’ under the Regional (America and Oceania) category by Pharmaceuticals Export Promotion Council of India.
  • Received the BS OHSAS 18001:2007 certifying the occupational health and safety management system of our manufacturing facility at Dundigal.
  • Received ISO 14001:2015 certifying the environmental management system of company’s manufacturing facility at Dundigal.
  • Received ISO 9001:2015 certifying the quality management system of manufacturing facility at Dundigal.


  • Awarded the ‘Top Exporter/Importer’ by the Hyderabad Customs Commissionerate, Customs and Central Excise, Government of India.


  • Awarded the ‘Excellence in Export Performance’ at the Federation of Telangana and Andhra Pradesh Chambers of Commerce and Industry instituted by Surana Group of Industries, Secunderabad.
  • Awarded the ‘Outstanding Export Performance Award’ under Formulations Fast Growing -1 category by Pharmaceuticals Export Promotion Council of India.


  • Awarded the ‘Top Exporter’ by the Hyderabad Customs, Customs and Central Excise, Government of India.
  • Awarded the ‘Outstanding Export Performance Award’ under Formulations Silver Star category by Pharmaceuticals Export Promotion Council of India.


  • Awarded the ‘Best Exporter’ by the Hyderabad Customs.
  • Awarded the ‘Express Pharma Excellence Awards 2019’ under the turnover base Rs 500-2000 crore category organized by the Express Pharma and Optel Group.
  • Awarded the ‘Telangana Best Employer Brand Award’ at the 14th Employer Branding Awards organised by the Employer Branding Institute, India.

Major events and milestones

  • 1978: Incorporation of the Company by P.V.N. Raju.
  • 2000: Set up the in-house R&D facility at Dundigal, Hyderabad.
  • 2003: Received USFDA approval for the manufacturing facility at Dundigal.
  • 2004 -2 005: Launch of Enoxaparin Sodium Injection (Cutenox) in India and Rest of the world markets.
  • 2007: Capital infusion of approximately Rs 1,000 million into the Company pursuant to private equity investment aggregating to approximately Rs 1,200 million with EILSF Co-Invest I LLC.
  • 2010: Launched Heparin Sodium Injection in the US.
  • 2012: Received the ‘Certificate of GMP Compliance of a Manufacturer’ from BGV Hamburg (Germany) for manufacturing facility at Dundigal.
  • 2014: Obtained USFDA approval for small volume parenteral manufacturing facility at Visakhapatnam.
  • 2014: Commissioned the Pashamylaram Unit-II manufacturing facility.
  • 2014: Received the ‘Certificate of GMP Compliance of a Manufacturer’ from MHRA (UK) for manufacturing facility at Dundigal.
  • 2014: Capital infusion of $100 million into the Company pursuant to private equity investment aggregating to approximately $ 200 million with KKR Floorline Investment.
  • 2016: Obtained USFDA approval for facilities at Jawaharlal Nehru Pharma City, Visakhapatnam.
  • 2016: Obtained USFDA approval for manufacturing facility at Pashamylaram.
  • 2016: Obtained USFDA approval for facility at the Visakhapatnam Special Economic Zone.
  • 2017: Fosun Singapore acquired 74% stake in the Company.
  • 2018: Received ANDA approval for Enoxaparin Sodium Injection USP for the US market.
  • 2018: Received ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%, our first Ophthalmic product approval.
  • 2019: Filed Dexrazoxane for Injection, company’s first filing with the National Medical Products Administration, China, and received clinical waiver.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.